If you’re a member of the media working on a story about brain trauma or brain health, we can connect you with the experts at Cohen Veterans Bioscience. Please don’t hesitate to contact us.
Senior Director, Communications
Cohen Veterans Bioscience
Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.
Follow Cohen Veterans Bioscience
- Read more
Published in the Journal of Neurotrauma, the article reviews factors that impact adoption and implementation of best practices for the management of traumatic brain injury (TBI). It also examines enablers of implementation and strategies for mitigating the barriers to optimal uptake.
- Read more
Cohen Veterans Bioscience and the European College of Neuropsychopharmacology (ECNP) have awarded the 2021 Best Negative Data Prize in Clinical Neuroscience to Chadi Abdallah, MD whose work inadvertently revealed mechanisms that may play a role in depression relapse following treatment with ketamine.
Cross-Platform Evaluation of Commercial Metabolomics Platforms to Support Precision Therapeutics ResearchRead more
As part of its RAPID-DxTM (Research Alliance for Precision Therapeutics, Innovation and Diagnostics) program, researchers from Cohen Veterans Bioscience (CVB) and collaborators conducted a blinded cross-platform analysis (or “bakeoff”) of commercially available assay platforms to inform selection in the conduct of neuropsychiatric biomarker research.
Cohen Veterans Bioscience, Stanford Brain Performance Center, and Brain Trauma Foundation Join Forces to Advance Precision Medicine for TBIRead more
Cohen Veterans Bioscience, Stanford Brain Performance Center, and the Brain Trauma Foundation announced a collaboration aimed at transforming the treatment recommendations and guidelines for mild traumatic brain injury (TBI) (inclusive of concussion) and advancing the field more broadly toward a precision medicine approach.
- Read more
The new PRISM 2 project, “Psychiatric Ratings using Intermediate Stratified Markers 2,” aims to identify quantitative biological features common across Alzheimer’s disease, schizophrenia and major depressive disorder, opening the possibility of developing targeted treatments irrespective of traditional diagnosis.